|Table of Contents|

Dynamic detection of circulating tumor cells HER2 in patients with gastric cancer and its clinical significance

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 07
Page:
1266-1270
Research Field:
Publishing date:

Info

Title:
Dynamic detection of circulating tumor cells HER2 in patients with gastric cancer and its clinical significance
Author(s):
DU Richang1; LI Yufang2; YANG Shasha1; WANG Linhui1; LI Jing1; QIU Junyong1; HUANG Junxian1
1.Department of Pathology；2.Emergency Department,Yuebei People's Hospital Affiliated to Shantou University Medical College,Guangdong Shaoguan 512000,China.
Keywords:
gastric cancer; circulating tumor cells; HER2; dynamic detection
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2023.07.016
Abstract:
Objective:To investigate the expression and dynamics of HER2 in circulating tumor cell(CTC) of gastric cancer,and provide clinical basis of the treatment of Herceptin in gastric cancer.Methods:The circulating tumor cell detection method(microfluidic chip separation technology) and immunohistochemical method(EnVision method) were used to detect the expression of CTC-HER2 in the blood of 86 patients with gastric cancer at one week before surgery,after surgery and after chemotherapy,and analyze their relationship with the expression of HER2 in histology.Results:The positive rates of CTC-HER2 were 46.51%(40/86),15.12%(13/86) and 11.63%(10/86) in 86 cases of gastric cancer before operation,after operation and after chemotherapy,respectively.The difference was statistically significant between the positive rate before operation and that after operation and after chemotherapy(P<0.05).The total positive rate of three tests was 61.63%(53/86).In histology,the positive detection rate of CTC-HER2 in HER2 negative patients was 29.17%（14/48）.Compared with histology,the difference was statistically significant(P<0.05).In the baseline test before operation,the consistency of CTC-HER2 value with that in histology was as high as 92.11%(35/38).Conclusion:Preoperative baseline detection of CTC-HER2 is particularly important.Multiple dynamic detection of CTC-HER2 can increase the positive rate of HER-2 and provide targeted treatment opportunities for gastric cancer patients whose HER2 is negative in histology.

References:

[1]LENGYEL CG,HUSSAIN S,TRAPANI D,et al.The emerging role of liquid biopsy in gastric cancer［J］.J Clin Med,2021,10(10):2108-2124.
[2]《胃癌HER2检测指南（2016版）》专家组．胃癌HER2检测指南（2016版）［J］．中华病理学杂,2016,45(8):528-532． Expert group of "Guidelines for HER2 Detection for Gastric Cancer(2016 Edition)".Guidelines for HER2 detection for gastric cancer(2016 edition) ［J］．Chinese Journal of Pathology,2016,45(8):528-532．
[3]LI TT,LIU H,YU J,et al.Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells［J］.World J Gastroenterol,2018,24(21):2236-2246.
[4]LI Y,YANG Y,LU M,et al.Predictive value of serum CEA,CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer［J］.Hepatogastroenterology,2011,58(112):2166-2170.
[5]ZHAO H,HUANG C,LIN M,et al.Dynamic detection of HER2 of circulating tumor cells in patients with gastric carcinoma and its clinical application［J］.Mol Med Rep,2022,25(5):187.
[6]RUGO HS,CORTES J,AWADA A,et al.change in topoisomerase 1 positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol［J］.Clin Cancer Res,2018,24(14):3348 3357.
[7]SINGLETON TP，STRIKLER JG．Clinical and pathologic significance of the c-erbB-2(HER-2/neu) oncogene［J］.Pathol Annu，1992,27(1):165-190．
[8] 李刚强，许珺，濮亚斌，等.乳腺癌患者外周血中循环肿瘤细胞的检测及临床意义［J］.现代肿瘤医学,2019,27(12):2114-2117. LI GQ,XU J,PU YB，et al.Detection of circulating tumor cell in breast cancer and clinical significance［J］.Modern Oncology,2019,27(12):2114-2117.
[9]PENG Z,LIU Y,LI Y,et al.Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients［J］.Biomark Med,2014,8(5):663-670.
[10]IWATSUKI M，TOYOSHIMA K，WATANABE M，et al.Frequency of HER2 expression of circulating tumour cells in patients with met astatic or recurrent gastrointestinal cancer［J］.Br J Cancer，2013,109（11）:2829-2832.
[11]LI YL,ZHANG XT,LIU D,et al.Evolutionary expression of HER2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance［J］.Clin Cancer Res,2018,24(21):5261-5271.
[12]GHOSSEIN RA,CARUSONE L,BHATTACHARYA S.Review：polymerase chain reaction detection of micrometastase and circulating tumor cells:application to melanoma,prostate,and thyroid carcinomas［J］.Diagn mol Pathol,1999,8(4):165-175.
[13]HUAI JG,CAO M,JIANG Y,et al.Evaluation of liquid biopsy in patients with HER2- positive breast cancer［J］.Biomed Res Int,2021,2021:6388492.
[14]DAISUKE M,YOSHIKAZU U,TAKAAKI A,et al.Clinical signifcance of circulating tumor cells in the response to trastuzumab for HER2 negative metastatic gastric cancer［J］.Cancer Chemotherapy and Pharmacology,2021,87(6):789-797.
[15]JORDAN NV,BARDIA A,WITTNER BS,et al.HER2 expression identifies dynamic functional states within circulating breast cancer cells［J］.Nature,2016,537(7618):102-106.
[16]WANG C,MU ZM,YE ZH,et al.Prognostic value of HER2 status on circulating tumor cells in advanced stage breast cancer patients with HER2 negative tumors［J］.Breast Cancer Research and Treatment,2020,181(3):679-689.

Memo

Memo:
广东省韶关市科技计划项目（编号：200812114531471）；广东省韶关市卫生健康科研计划项目（编号：Y20136）
Last Update: 2023-02-28